Dr. Ayed O. Ayed, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 15
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 304
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
FL license ME135547
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ascension St Vincent's Riverside Jacksonville, FL
- Baptist Medical Center - Nassau Fernandina Beach, FL
- Ed Fraser Memorial Hospital Macclenny, FL
Medical groups
- Cancer Specialists LLC (44 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 304
- Services billed
- 86,375
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 21,750 | 20 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2,300 | 18 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,066 | 25 |
| Injection, denosumab, 1 mg | 1,020 | 12 |
| Injection, granisetron hydrochloride, 100 mcg | 760 | 13 |
| Insertion of needle into vein for collection of blood sample | 700 | 210 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 570 | 192 |
| Injection, palonosetron hcl, 25 mcg | 460 | 14 |
| Established patient office or other outpatient visit, 30-39 minutes | 349 | 168 |
| Administration of chemotherapy into vein, 1 hour or less | 229 | 32 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Jacksonville, FL | 170 |
| Ondansetron Hcl Other prescribers in Jacksonville, FL | 93 |
| Dexamethasone Other prescribers in Jacksonville, FL | 78 |
| Gabapentin Other prescribers in Jacksonville, FL | 68 |
| Olanzapine Other prescribers in Jacksonville, FL | 62 |
| Letrozole Other prescribers in Jacksonville, FL | 59 |
| Anastrozole Other prescribers in Jacksonville, FL | 54 |
| Revlimid (lenalidomide) | 52 |
| Prednisone Other prescribers in Jacksonville, FL | 50 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Jacksonville, FL | 48 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 42 payments worth $858 in total to this clinician.
| Pfizer Inc. | $222 |
|---|---|
| Janssen Scientific Affairs, LLC | $117 |
| Agios Pharmaceuticals, Inc. | $81.70 |
| Novartis Pharmaceuticals Corporation | $80.77 |
| Janssen Biotech, Inc. | $76.43 |
| Tempus Ai, Inc | $56.75 |
| Genentech USA, Inc. | $53.05 |
| Daiichi Sankyo Inc. | $39.12 |
| Food and Beverage | $858 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 18 industry-funded studies in 2025, from 7 companies. The companies reported $1,131,736 in research payments for these studies, mostly to the institutions running them.
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun)
Genentech, Inc. - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT06191744 - Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Daiichi Sankyo Inc. · Active, not recruiting · NCT05555732 - A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose …
AstraZeneca UK Limited - M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated …
AbbVie Inc. - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT05451810 - M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
AbbVie Inc. - Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (ACRUE)
AstraZeneca UK Limited - M25-274 - A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Sma…
AbbVie Inc. - A Phase III, Open-label, Randomized Study of Osimertinib with or without Datopotamab deruxtecan (Dato-DXd), as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally A…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.